Diabetes

The Pharmacy Times® Diabetes resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?

FDA Expands Use for Insulin Aspart Injection Pumps

Officials from the FDA have expanded the label of insulin aspart injection pumps, 100 u/mL (Fiasp, Novo Nordisk) to include use in insulin infusion pumps.

Choosing the Best Medication for Diabetes is Tricky

Treatment depends on the patient, but adherence to the ever-changing guidelines is key.

Researchers Find Link Between Diabetes in Young Adults and Cardiometabolic Risk Factors

A study has found that young adults with diabetes have high rates of cardiometabolic risk factors such as adiposity, blood pressure, chronic kidney disease, and history of cardiovascular disease. These risk factors can lead to an increased disease prevalence and mortality rate among these young adults as they age.

Study Links Antidepressants and Risk of Gestational Diabetes

The study aimed to determine the association between antidepressant classes, types, and duration of use during pregnancy and the risk of gestational diabetes.

Canagliflozin Approved by FDA for Diabetes-Related Kidney Disease

Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).

FDA Approves First Oral GLP-1 for Type 2 Diabetes

The FDA has granted approval of Rybelsus (semaglutide) oral tablets 7 mg or 14 mg to Novo Nordisk. The drug is the first oral glucagon-like peptide (GLP-1) receptor protein treatment for type 2 diabetes.

Study of Early Combination Treatment Demonstrates Positive Results for Type 2 Diabetes

A recent clinical study demonstrated positive long-term benefits of the early intervention combination treatment of metformin plus vildagliptin (Galvus, Norvartis), a dipeptidyl peptidase-4 [DPP-4] inhibitor, for type 2 diabetes (T2D).

Glucagon Injection for Severe Hypoglycemia Granted FDA Approval

The glucagon injection is designed to reduce the steps and time needed to prepare and administer medicine for severe hypoglycemia.

Pain Medication Associated with Greater Risk of Hypoglycemia

Recently published in Science Daily, the study was based on the investigating team’s analysis of more than 12 million reports from the FDA Adverse Effect Reporting System (FAERS) and Adverse Event Reporting System (AERS) databases.

There Is No Sugar-Coating Gestational Diabetes

Help pregnant women with diet, other lifestyle changes, prevention, symptoms, and treatment.

Management of Patients With Diabetes and Cardiovascular Disease

Patients who have diabetes often have—and are often unaware they have—cardiovascular complications. These complications can change the trajectory of this disease and are costly for society.

Nasal Powder Glucagon Receives FDA Approval

The FDA has granted Eli Lilly and Company approval for its nasal powder glucagon (Baqsimi) for emergency treatment of severe hypoglycemia.

+ Load More

The Pharmacy Times® Diabetes specialty page serves as a hub for all clinical news and articles related to the condition. The coverage includes best practices for treating diabetes, from the early signs and symptoms like increased thirst, fatigue, and blurred vision; and addresses the primary causes of diabetes – the destruction of insulin-producing beta cells of the pancreas.

The Pharmacy Times® Diabetes condition center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of novel diabetes therapies, and the newest data from all phases of clinical trials and studies in the space.